Navigation Links
UM Ventures Announces Collaboration Between UM School Of Medicine's Dr. Frank Robb and Fina Biosolutions

BALTIMORE, July 11, 2013 /PRNewswire/ --  University of Maryland (UM) Ventures announced today a collaboration between Frank Robb, Ph.D., at the Institute of Marine and Environmental Technology, and Department of Microbiology & Immunology at the University of Maryland School of Medicine, and Rockville, Maryland-based Fina Biosolutions LLC to devise new ways to manufacture a key component used in many vaccines. The international nonprofit organization, PATH, which spurs new innovation with the goal of delivering high-impact, low-cost global health solutions such as lifesaving vaccines, will fund the partnership's development efforts as part of its pneumococcal vaccine project.

"A new and improved vaccine production method is the goal of this public-private partnership between my lab and Fina Biosolutions," said Dr. Robb. "It is designed to yield broader availability of an important vaccine component, which is highly effective, but prohibitively expensive for some applications, particularly in the developing world."

Dr. Robb, whose lab is in the Institute of Marine and Environmental Technology, has studied a unique group of microbes found in extreme environments ("extremophiles"). These astonishing organisms, many of them from marine hydrothermal vents (so-called "Black Smokers"), have chaperone systems that enable them to survive and even thrive in extreme heat and harsh chemical conditions. When the extremophile chaperone systems are transferred to ordinary bacteria, they become more stable to heat or solvent exposure. Dr. Robb's team has developed several technologies, patented by the University of Maryland, which are based on industrial applications of his research. These include systems for improving the stability and function of manufactured proteins for a variety of purposes, such as vaccines and specialty enzymes.

"We are pleased to be working with organizations that share FinaBio's mission to help make conjugate vaccines affordable for the emerging markets. The partnership with PATH and the University of Maryland will allow us to achieve this goal and to help to make vaccines that will save countless lives," said Andrew Lees, Ph.D., Scientific Director, Fina Biosolutions.

"Following on the heels of our Wellcome Trust-Bharat Biotech collaboration formed last year," said Phil Robilotto, Assistant Vice President, Office of Technology Transfer, UMB, "UMB's Office of Technology Transfer, in conjunction with UM Ventures, is very happy to be facilitating more of these important public-private partnerships on behalf of the campus and its investigators, such as Dr. Robb." UM Ventures is designed to help facilitate the commercialization of technologies developed by UM researchers at the University's Baltimore and College Park campuses.

About Fina Biosolutions, LLC

Fina Biosolutions LLC is a private, research and development-stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. For more information, see

About PATH

PATH is an international nonprofit organization that transforms global health through innovation. We take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions from lifesaving vaccines, drugs, diagnostics, and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partners empower people to achieve their full potential. For more information, please visit

About UM Ventures

UM Ventures is an ambitious joint research commercialization effort of the University of Maryland, Baltimore (UMB) and the University of Maryland, College Park (UMCP). UM Ventures is a central part of an initiative called University of Maryland: MPowering the State. The program has combined the entrepreneurial efforts of the two powerhouse universities that together do more than $1 billion a year in externally sponsored research. UM Ventures is bringing innovative technologies to the market and expanding collaborations with industry. Visit to learn more.

SOURCE UM Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Files Defamation Lawsuit
2. Practice Fusion Announces $34 Million in Financing Led by Artis Ventures
3. Pappas Ventures Names Pat Gage to Scientific Advisory Board
4. SJF Ventures Completes Oversubscribed Series A Round for BioSurplus
5. Sunpeaks Ventures Announces Second Quarter 2012 Results
6. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
7. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
8. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
9. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
10. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
11. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):